Please note that the details of this Challenge are no longer open. This challenge is withdrawn and is no longer accepting new submissions. You can:
Challenge AstraZeneca Challenge: Determination of Free Drug Concentration in Lung
AstraZeneca Challenge: Determination of Free Drug Concentration in Lung
Award:  $25,000 USD
Deadline: Withdrawn
Active Solvers: 131
Posted: Sep 05 2016
Challenge ID: 9933829
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

The pharmacological effect of inhaled drugs normally correlates with the free drug concentration in the lung tissue. However, accurately determining the free drug concentration of drugs in the relevant lung tissues poses a great challenge to the scientific community. Current methods are rather limited and do not provide the required accuracy that would lead to a sound understanding of drug behavior and pharmacokinetics. Hence, AstraZeneca aims at identifying a novel method that can overcome current limitations. 

This Theoretical Challenge requires only a written proposal.

Overview

Inhalation is a common approach to administer drugs aimed at the treatment of lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Designing drugs for inhaled administration involves many challenges of which one is to secure duration of the pharmacological action of the drug. One strategy to achieve exposure in the lung over an extended period of time is to administer a poorly soluble compound. In the lung the drug will slowly dissolve and expose the tissue to achieve the desired pharmacological effect. 

Pharmacological effects normally correlate with the free drug concentration. However, accurately determining the free drug concentration of drugs in the relevant lung tissues poses a great Challenge, as this is not free from interferences, especially from solid undissolved particles of the drug. Therefore, AstraZeneca wishes to identify a method that can solve current limitations and provide valuable insight into understanding of inhaled drugs behavior in vivo.

To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions. 

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 5, 2016. Late submissions will not be considered.

 

ABOUT THE SEEKER

AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research. 

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge
InnoCentive Trust Partners